Medical News

[ Torax Medical Receives CE Mark For Its LINX R Anti-Reflux Treatment ]

Torax Medical Receives CE Mark For Its LINX R Anti-Reflux Treatment

Torax Medical Inc., a medical device company focused on the minimally invasive treatment of gastro-esophageal reflux disease ( GERD ), has received CE Mark for its LINX® Anti-Reflux treatment.. The company has started commercial launch of the LINX device at select centers in Europe. Patients with GERD typically experience burning pain and tissue damage, the result of stomach juices refluxing into the esophagus. This is due to a defective esophageal sphincter muscle between the esophagus and the stomach. These juices, which include acid and bile, are harmful to the lining of the esophagus and are prevented from entering the esophagus when the sphincter muscle is normal. The LINX device is designed to augment an abnormal sphincter and restore its barrier function. "The LINX device has been implanted in over 150 patients in Europe and the U.

Detection Of Precancerous Condition Improved By New Form Of Endoscopic Scanning

Cancer of the lower esophagus develops almost exclusively in patients with Barrett's esophagus, an otherwise benign complication of esophageal reflux that affects approximately 3 million Americans. Although the prognosis of patients diagnosed with esophageal cancer is poor, the chances of successful treatment increase significantly if the disease is detected at an early dysplastic stage. Now, a new endoscopic scanning technique developed by scientists in the Biomedical Imaging and Spectroscopy Laboratory (BISL) at Beth Israel Deaconess Medical Center (BIDMC) has proven successful in the early detection of dysplasia in Barrett's esophagus. The results of the study, which appear in the April 11 on-line issue of the journal Nature Medicine, could help clinicians to diagnose esophageal cancer at an earlier stage, when the condition is still treatable.

Women And Digestion: New Survey By Enzymedica Identifies Surprising Impact On Self Image And Well-Being

Digestive disorders are epidemic in the US and millions suffer regularly. While gas and bloating is common to both sexes, it is widespread in females, particularly during menses. Hoping to take a closer look at the problem, the digestive enzyme experts at The Enzyme Research Group, (ERG) in association with Enzymedica, Inc., conducted a survey of U.S. females. The results illustrate how impaired digestion can have troubling effects on women's lives. The study uncovered that an overwhelming 96% of women report some sort of digestive issue, including 55% who suffer regularly. 40% said they have been diagnosed with a digestive disorder, and Heartburn and GERD topped the list. The researchers found that 45% experienced bloating that cycles with their periods, and nearly a third said that digestive upset was the norm during their 'monthly visitor.

Outcomes Of Patients Dismissed From The Hospital With Noncardiac Chest Pain

The growing number of Americans with cardiovascular disease has caused a heightened sensitivity in the evaluation of chest pain. In a study published in the April issue of Mayo Clinic Proceedings researchers reported that patients dismissed from the hospital with noncardiac chest pain continue to experience cardiac events, which may highlight a need for more aggressive cardiovascular risk factor management in this population. Noncardiac chest pain is defined as a substernal chest pain in the absence of significant epicardial coronary artery stenoses. Noncardiac chest pain is attributed to a variety of disorders, including gastroesophageal reflux disease ( GERD ) and esophageal hypersensitivity, panic attack, musculoskeletal pain and microvascular disease (cardiac syndrome). Researchers identified 320 patients with a diagnosis of noncardiac chest pain to determine the frequency of gastrointestinal (GI) consultations and testing, and to identify the frequency of cardiac death.

Proton Pump Inhibitor DEXILANTTM dexlansoprazole Now Available In U.S. Pharmacies

Takeda Pharmaceuticals North America, Inc. today announced that DEXILANT™ (dexlansoprazole) delayed release capsules are now available in United States (U.S.) pharmacies. Takeda recently announced that the product trade name for dexlansoprazole in the U.S. would be changed from KAPIDEX™ to DEXILANT. The formulation, indication and approved dosages of DEXILANT remain the same as that of KAPIDEX, which was originally approved by the U.S. Food and Drug Administration (FDA) in January 2009. After receiving reports of dispensing errors with KAPIDEX, Takeda, in coordination with the FDA, determined that in the interest of patient safety a name change would be the best way to minimize future errors. DEXILANT is a once-daily, oral medication indicated for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease ( GERD ), the healing of erosive esophagitis (EE) and the maintenance of healed EE.

Fast: [10]

Medical News © Nanda
Designer Damodar